Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Conference · 2026-11-10
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Thanks, everyone, for joining us here at Guggenheim's innovation, health care innovation conference. I'm here with Mineralis. So John Congleton, CEO of Mineralis. Joining us, I'm Seamus Fernandez, one of the senior biopharma analysts here at Guggenheim. So, John, you know, we're just weeks away. From Laura under stats, you know, December 22, PDUFA date. So before we get into the regulatory and launch details, we just give us a sense of where the company stands today. What are the most important things to get right over the next couple of months?
Yeah, no, James. Thank you. Thanks to Guggenheim team for the invite to the conference was very productive. Enjoy obviously talking about what we're doing on the heels of the American Heart Association, where I was this past weekend in Chicago. I get excited about, I think, the focus on hypertension, the focus, frankly, on progressively getting patients to goal, and even sometimes more aggressively, the enthusiasm that we're seeing building around aldosterone as a target and the ASIs. For us, And we'll get into it in more detail, but it's a matter of having all of the key... Vectors, if you will, so market access, the med-ed and dissemination of information around aldosterone and ASIs, the sales team, which we said we have fully in place right now, and all of the back office brand marketing materials ready to roll so that, you know, presuming we have positive news on the action date, we can quickly transition into getting more understand into the hands of physicians and patients in 2027. Great.
And I mean, obviously, your commercial background has a company, you know, extremely well prepared for the launch. But, you know, how are you thinking about the opportunity for laryngostat and the ASI class, you know, sort of broadly speaking? You know, it's a market dominated by generics, and there are different approaches that you could kind of take to attacking the category.
Yeah, I mean, as you know, I mean, I started my career 40 years ago carrying the bag, selling in the hypertension space when all of these generics were branded. A lot of great innovations brought into the space at that time. But if we fast forward to where we are now, we still have over half of the patients treated or not at goal. Goal progressively comes down. Back when I was rep, it was 140. It's now 130. There's a lot of argumentation to get down below 120 to really confer the benefits that one would You know, I get asked a lot of questions, and I'm sure you'll ask, you know, difference between Baxterstatt and Loranderstatt. And those are important distinctions, but I think fundamentally. That's not what this is about. It's about the 20 million patients who are on two or more meds cannot get to goal with what's currently available, and a lot of these patients have trialed multiple drugs or have added multiple drugs and are just getting incremental value and not getting aggressively to that goal. So from my standpoint, as we think about the introduction of lorunderstat, it is frankly more about Juxtaposing lorundersatz profile to alpha blocker, beta blocker, calcium channel blocker, MRA, because that's where those 20 million patients really need value. And then once a physician is kind of bought into, yes, ASIs are probably where I need to go, then we can talk about some of the distinctions, where there are similarities, where there's differences with Baxter stat. But I think that's where the real opportunity is to really tap into this market. Got it.
You know, the. There's a lot of, I guess, sort of distinctions as we look at just the growing acceptance of GLP-1s. There is an impact of GLP-1s on blood pressure that can be seen. Does that have much of an impact on the market opportunity from your perspective, or is that just kind of an incremental tool?
I think it's going to be a foundational tool. The data that we're seeing with the anti-obesity treatments, whether it's single G, double G, triple G, are going to be foundational in accord to the treatment of cardio kidney metabolic, the CKM disease conditions, but they're not the silver bullet. Right? What we've seen to date is about a five millimeter mercury reduction in blood pressure, mostly across anti-obesity treatments, and frankly, historically to bariatric, to diet, and exercise. There's certainly some that respond more than that, some that respond less than that. I don't know that it meaningfully cuts into the opportunity for lorundrostat. You know, we've looked at our data and looked very deeply at response relative to BMI, because there's clearly a link, we think, between visceral adiposity and aldosterone and uncontrolled or resistant hypertension. And frankly, independent of BMI, you're seeing really robust, clinically meaningful reductions, which we'll understand. So I don't think one eliminates the need for the other. I could actually see them coexisting well as part of a broader CKM treatment paradigm. And we've had some of our KOLs. You know, opine that that's where they see this going, that you're going to need to target obesity with whatever treatment you want, but you also have to really focus on aldosterone as well. Got it.
And when we look at just sort of the data itself and the sort of value add of the ASIs. Let's obviously focus on Lorenda Stat and the value add that it offers. Just walk us through the data, and really, I think that kind of brings us to the label. What do you hope to see in the label for Lorenda Stat, and what are the opportunities for differentiation?
Yeah, you know, it's interesting. Three, four years ago, in a dialogue with the agency, they Eliza Thompson kind of positioned the label as it's a tool to inform prescribers on how to use a drug, I mean, fundamentally. And so then if you think about. So hypertension in the hands or being treated by a primary care doctor, by a nephrologist, by a cardiologist, they're not just thinking about hypertension, right? There's comorbidities, and I think that's what informed our clinical development program going back four years ago. It's why we did two really distinct pivotal studies, launch HTN in the real world. You know, come as you are with whatever drugs you're on, add a little understand, see the benefit you get. We know we saw a 19-millimeter absolute, 11.7-millimeter placebo-adjusted in that real-world population, primary care. That's who they're treating. Cardiologists, on the other hand, tend to really maximize the background treatments. They follow AHA guidelines as far as treatments they pick. They're going with, for the most part, maximal dose, and so we did that, studied with the Cleveland Clinic, where we took patients off the background meds, maximized an AHA background treatment, followed them for three weeks, and only randomized those that could be treated. We could not get to go, so truly confirmed, and so that... It becomes a really distinct data set for cardiologists, and then we did our Explore program, CQD, OSA, because, again, we're seeing comorbidities of either CQD and or OSA and or obesity, and the latter study, Explore OSA, was not part of the label submission, but Explore CQD was. So each of these three distinct studies I think are very informative to the constituents that treat uncontrolled and resistant hypertension. It's what we put into our data package. It's what we put into our label. It'll be part of the dialogues with the agency as far as which pieces of each of the studies make it into the label. But as I look at just kind of a base case assumption, LAUNCH-H10, I think, is the largest study with an ASI and uncontrolled and resistant hypertension, shows really meaningful blood pressure reduction, shows a very clear safety profile, and that is a base case in the label, I think, is a strong hand for us to make argumentation for the use of the runner stat, third line or later, broadly, and a competitive profile relative to Baxter stat specifically.
Got it. When you look at some of the side effects or potential safety issues that can be of concern, what are some of the factors that you think will weigh favorably for lorundostat in particular relative to whether it be MRAs or directly versus baxter stat?
Yeah, I think where we're fortunate is the main adverse events of interest are Mechanistically driven are aligned to what physicians are used to looking for with ACE inhibitors and ARBs and MRAs, and that is the electrolyte changes, so the elevation of potassium, the depletion of sodium, changes in EGFR. And hypotension. So those are the four main ones to look for. And I think what we've seen with lorunderstat, given its selectivity, its ideal, what we think is ideal, half-life of 10 to 12 hours, you're not compromising efficacy to have really pretty modest changes on electrolytes. And the nice thing is, and I've conveyed this to people before, the profile of lorunderstat fits a workflow that physicians have been accustomed to for 40 years. And that was attuned by ACE inhibitors and ARBs. In other words, you initiate this drug, within two to four weeks, you're going to see the bulk of your blood pressure response. You're going to see changes in electrolytes. You're going to see changes in EGFR. If you're going to see symptoms of hypotension, you're going to see those pretty rapidly, and then they stabilize. And we even showed that at AHA this past week and with our open-label TransformHTN data through 48 weeks, EGFR, aldo-renin, sodium, potassium, everything stays stable within that first two-week, you know, kind of temporal frame. So it fits the workflow for physicians. It's a very modest change. Given our half-life, if you have a patient that does have an extreme response with that on-target effect, you can either reduce dose or just back off and then evaluate, do you do a re-challenge? Got it.
Let's talk a little bit more about the commercialization of the product. So, what are the choices that you see in market today that AstraZeneca has made to kind of promote Bax Fendi, and then how are you going to kind of approach the market?
Yeah, I think from what, you know, outside looking in, I think AstraZeneca in support of Baxterstat is following kind of a path that we are. I think they've looked at the high volume prescribers, third line or later, and are directing efforts against them. You know, we've identified in the past about 45,000 doctors, plus or minus the control, 40 to 50 percent of the prescribing in that latter line case. What I think has been interesting with the Baxter Stat launch data that we've gotten, the prescription level data, prior to their launch, it was largely primary care, about 60%, 40% cardiology. What we're seeing in the actual scripts is about 55% primary care, about 20%, 25% cardiology, and the nephrologists are showing up about 20%. Which is a bigger penetration than you would see typically in broad third or fourth line use. I actually think that's a good thing, a good foretelling sign for us, because I think we've got a really robust data set and argumentation for nephrologists to use Lernerstat and hypertension overlapping with CKD. So that's part of how we're thinking about, you know, making sure we're directing effectively to that nephrology segment as well. But I think that narrow focus on those high-volume prescribers was how we thought about the plan. It's how we continue to think about the plan. It seems to be what's resonating in the early days of what we think is a very strong launch for BaxterStat.
Great. And in terms of just the, there was one kind of important development, I think, that may help you and the team, which is the importance of Medicare. Can you talk a little bit about, you know, the importance of Medicare? I think AstraZeneca talked about not really making the, you know, sort of the timeline for, you know, Medicare formulary inclusion. Is that something that is an opportunity to actually balance out, you know, sort of almost launch availability timelines for Lerunderstat and Baxterstat?
Yeah, there were, I got early questions that, you know, since AC missed the bid cycle with Baxter stat, you know, presuming we get approved end of the year, we'll miss the bid cycle. Does that mean that, you know, for us, 27 is a wash for Medicare? And I, my answer to that's no. Yes, there are bid cycles, and so from our planning standpoint, 2028 is probably when we would be on full formulary. Medicare has its own flexibility. It could choose to include drugs in the formulary at any time, so it could come sooner, but the bid cycle, kind of within a standard rollout, would mean 2028 full formulary. But there's clearly an exception pathway to get patients who have Medicare as their insurance, get them access to ASIs. In fact, we're seeing within the current Baxter set prescription data, about a quarter of all those patients are Medicare. So even though you're not on formulary, it doesn't mean that you cannot get access to it. There's a few more hoops you have to walk through, but that's why part of our commercial build includes a PSP and a hub to Make sure that we've got staff that are knowledgeable of that space, of that process, that can work with physicians, their office staff, as well as patients, and get them access if a doctor and a patient decide or understand is something they want to pursue. Okay.
And historically, you know, the thought process around, you know, launching a drug into a very broad primary care market is that, you know, it's spend of $300 million, like right out of the gates, you should just be prepared for it. And then hopefully, you know, you can have a great launch. How do we think about that in the context of today's market? There's obviously been a lot of evolution relative to kind of launch spend and expectations without giving guidance for 2020. Yeah.
If you want to, go for it. Nope, nope, nope. Thanks for the caveat. Yeah, a couple of things. I come back to hypertension is large, and if you looked at, you know, and counted every number of every doc that ever wrote a prescription, it's a big universe. But it's also very narrow when you think about how we've positioned this drug, third line or later. When you think about where's the high volume prescribing population, so about those 45,000. So that suddenly narrows the feet on the street that you need. I've also made the point that launching in 2027 as a small biotech is easier than it would have been 20 years ago, and it's because of all the little devices we have in our pocket and the technology and things like Doximity and Open Evidence and Facebook. These are Really efficient ways for a small biotech to tap into and build awareness, enthusiasm, and excitement about a molecule beyond just the feet on the street. So it's not 20 years ago, it was an army of sales reps to really disseminate information. I think the combination of efficiency of promotional tools that we have available now, coupled with the narrow pool that really drives a big percentage of these ladder line treatments, benefits us. And then couple that, frankly, with the profile that Lerunderstat has. You know, we've talked in the past, if you do a meta-analysis, we're adding the third-line agent to a patient that's not a goal, you incrementally get about 5 millimeters of mercury reduction. We're seeing 19. I mean, these aren't just incremental introductions that we're talking about. These are foundational. They're the kind of numbers that get, like we saw in our open-label extension, 56% of the patients to goal who had not been a goal. And so I think having a narrow target audience, having really efficient, broad dissemination tools that are ready, and having the kind of molecule we have, I think it gives us a nice setup going into a launch in 27.
And there are big differences in individual patient populations. African-American patients, black patients, you know, typically can suffer from resistant hypertension. You also have, you know, a massive number of patients out there. How has Landerstatt performed in the different patient populations? Is there much differentiation?
Yeah, you know, early days, we actually... I'm going back to proof of concept. We tried to use renin as a target to identify responders. This drug worked whether you had low, normal, or high renin. We thought there was a signal in obesity. We looked at response relative to BMI. Drug worked great. Low, medium, or high BMI. We did a force plot with LAUNCH-HTN, the largest study in an ASI that we did with lorunderstat. Male, female, race, like you said, whether white or black, African-American, Latino, BMI. This drug consistently is left-shifted, no matter how you look at it, which... For a company that was trying to find the target, the tell, it's like, okay, now what do we do? But it's a really good scenario to have. And physicians see that, and they're really amazed. Now, that said, there will be within that third and certainly fourth line some really specific ones we're going to hone in on. We went to great intent to ensure we had diversity in our study populations. Advance was 53 percent black African-American. Launch was 28 percent. And if you look at some of the prescribing patterns right now, even with Baxter said, it's very regionalized. We know that rates of uncontrolled and resistant hypertension are overrepresented in the southeast in the old Rust Belt, if we can still call it that. There's a significant proportion of black African-American patients there. We know they're disproportionately affected by uncontrolled and resistant hypertension. So to have that data and go out and speak explicitly to those prescribers is a real benefit for us. But, you know, again, broadly, I think our data just highlights aldosterone is the key that currently is not being properly addressed with any therapeutic out there. Spiro is the only one that's out there, and nobody wants to use it.
Got it. And then, you know, let's talk a little bit about just CKD, additional studies that, you know, could be conducted. Obviously, AstraZeneca has massive outcomes programs out there. What is the necessity, in your view, of the outcomes programs for laryngostat versus, you know, small additional studies that are, you know, supportive or directionally supportive?
Yeah, outcomes are really interesting. A couple of points on that. One, we will have an outcomes claim at approval. So in 2012, the FDA came out and said any drug that lowers BP will get a statement in their indication that says the reduction of blood pressure is linked to reduced risk of stroke, MI, and cardiovascular events. So that piece is out there. And as we go out and do market research physicians, we just ask the question, how important are outcome studies relative to the fact that we're lowering BP? And it's a rare minority that say, well, I'd like to see it. And then we ask the question, well, do you not believe BP lowers outcome? And it's like, well, yeah, I believe that. I still want to see it. So, you know, there's going to be some value to having the outcomes data, but I think the evidence is pretty irrefutable, and even this weekend at AHA, they looked at 140 versus 120 as a goal, and those at 120, there's about a 20 to 27 percent reduction in risk of CV and stroke outcomes. So, I mean, the data just continues to pound, get the blood pressure down, you're going to see that benefit. So I don't know that. Just to set expectations, you're going to see us come out with a 5,000 or 10,000 patient outcome trial. But to your point, I think we've done it to date and acknowledged that it's not just hypertension, but there are comorbidities, and adding data around the edges of that to really help us solidify the profile in hypertension is what we're going to continue to do. We did it in OSA. We did it in CKD. We may go deeper in some of those. We may look at some other indications. And that's part of what I've got the team really digging into in talking with advisors and looking at the profile of Leronderstat, you know, where do we continue to bolster that profile that we think can be best in class?
Yeah. And what would you say, you know, from your perspective, the most underappreciated opportunity for the ASI category and the most underappreciated opportunity for Leronderstat and obviously by extension Mineralis?
And by extension, what? Mineralis. I think just fundamentally tapping into those 20 million patients. You know, it is such a huge market opportunity. It has such a massive impact. We have a saying within the company, my team will shoot me for saying this, but create more better days. You know, I think that's what fundamentally we have an opportunity to do. The linkage of controlling blood pressure in reducing risk of outcome, reducing risk of dialysis, stroke, heart failure, all the implications of that, I think that is at a purpose humanistic level what's core for us. But that translates significantly into how do we penetrate deeper into those 20 million patients that are not at goal. Yes, we want to look at other indications, but just the job at hand right in front of us is a huge value driver. I think it's underappreciated for this class. I do think this, and I'll pull Baxter said into this, I think the ASIs are the right drug at the right time for what is. Driving a lot of poor outcomes for cardiorenal metabolic patients. And by extension, that opportunity for ASI translates for Lirondrastat because I think we've got just a fabulous data set to inform prescribers. And then the success we have with Lirondrastat is Mineralis. Just enables us to continue to grow as an organization. Look at how we continue to expand the data around Lirondrastat, but also look at are there other opportunities for us to bring in and maximize value.
Got it. And just in terms of the cash runway for the company, and, you know, maybe just help us think about, you know, kind of the long-term sort of strategic, how you think about strategic options long-term for mineralis.
Yeah, so we had an earnings call last Wednesday. Into Q3, we noted we have $625 million in cash. That gets us into 2028, obviously, including the launch of the product. We also did a debt facility to deal with Pharmacon this past summer for $500 million, pulled $100 million. At the time of closing, we have $150 million upon approval, and then that leaves $250 million in two different tranches that are somewhat at our discretion and driven by sales achievement. And all of that collectively, we feel comfortable, supports the launch commercial plan for Lerunderstat. Strategically, where do we go? I kind of alluded to it earlier as far as growing lorunderstat by extension grows mineralis. We're looking at opportunities to drive value within that. You know, we've always talked about partnering will be a part of our story. We're not going to launch this drug outside of the U.S. on our own. There are complexities with that given MFN, but Our goal has always been, how do we get more understat to as many people as appropriately as we can without risking, at this point in time, the U.S. marketplace? So strategically, that's going to be an important factor within that, and just looking to continue to drive value within all those different levers we have at hand.
Well, definitely exciting times. Going to have several busy months and an extremely busy 2027 ahead, so exciting times. John, thanks so much for joining us here again this year.
You bet. Great to be here, and we'll all have a Merry Christmas.
0:00 to 25:28 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
Thanks, everyone, for joining us here at Guggenheim's innovation, health care innovation conference. I'm here with Mineralis. So John Congleton, CEO of Mineralis. Joining us, I'm Seamus Fernandez, one of the senior biopharma analysts here at Guggenheim. So, John, you know, we're just weeks away. From Laura under stats…
Jon Congleton: Yeah, no, James. Thank you. Thanks to Guggenheim team for the invite to the conference was very productive. Enjoy obviously talking about what we're doing on the heels of the American Heart Association, where I was this past weekend in Chicago. I get excited…